Zimbabwe has declined a major US health deal worth $367m (£272m) spanning five years due to the United States' insistence on sensitive biological samples.
This rejection became public after a government memo dated December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the agreement was "unbalanced".
An official spokesman has since clarified that the United States was demanding access to biological samples for scientific study and profit but was not willing to share the resulting advantages from future vaccines.
"We will now turn to the challenging and unfortunate process of ending our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had provided over $1.9bn in health funding to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has urged more dialogue to reach a deal acceptable to both sides so the nation's critical HIV treatment initiative can proceed.
Broader Context
This rejection follows a comparable case in Kenya, where a court blocked a similar deal with the US after concerns were raised about the security of citizens' medical information.
After resuming the presidency recently, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
The agency had administered assistance for the American government, but Trump stated its spending was "wasteful" and his government was seeking direct bilateral deals to boost transparency and accountability.
According to statements, 16 nations in Africa have so far signed similar health pacts, representing over $18.3bn of fresh investment.
Specifics of the Declined Deal
The money for Zimbabwe would have supported "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration might have yielded immense benefits for the people of Zimbabwe, particularly the 1.2 million presently receiving HIV treatment via US-supported programmes," the Ambassador said.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"The proposal required Zimbabwe to share its biological resources and data over an extended period, with no corresponding assurance of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that might be developed from that provided information," Mangwana explained.
"Effectively, our nation would provide the raw materials for scientific discovery without any assurance that the resulting innovations would be available to our citizens should a new disease outbreak emerge."
Sovereignty and International Frameworks
Mangwana further noted that the US's withdrawal from the global health body and its push of bilateral deals were upending systems already set up via the international organization.
Mangwana cited its Pandemic Benefit-Sharing scheme designed to deal with potential pandemics.
"This mechanism is intended to ensure that when a nation provides its data, the resulting advantages – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the resources to develop them."
These objections regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We are open to continued dialogue with our American counterparts on how future collaboration might be arranged in a manner that respects the independence and dignity of both nations."
Health Experts Response
Medical experts stated it recognised the government's concerns, but urged that talks must proceed since much of the country's Aids initiatives were funded by foreign aid.
"In cases where specific concerns arise, including those relating to data governance or agreement terms, these can frequently be addressed via technical clarification and mutually agreed protections," the group added.
The halted deal emphasises the complex tensions between receiving crucial international aid and safeguarding national sovereignty in an ever more data-driven world.